Last updated: August 22, 2026
Cosyntropin is a mature, niche diagnostic pharmaceutical used primarily in adrenocorticotropic hormone stimulation testing for suspected adrenal insufficiency. The market has low clinical substitution risk but limited volume, concentrated supply, periodic shortages, and pricing that can rise sharply when manufacturers face production or distribution constraints. Cortrosyn, marketed by Amphastar Pharmaceuticals in the United States, is the principal branded commercial reference product. The product’s financial outlook depends more on supply reliability, hospital purchasing, and reimbursement than on patent protection or new indications.
What is cosyntropin and how is it used?
Cosyntropin is the synthetic amino-terminal 1-24 fragment of human adrenocorticotropic hormone, also known as synthetic ACTH. It stimulates the adrenal cortex to produce cortisol and is used in diagnostic testing for adrenal insufficiency.
The standard test typically administers 250 micrograms intravenously or intramuscularly, followed by serum cortisol measurements at baseline and after stimulation. The FDA labeling identifies use in evaluating adrenal cortical function and differentiating primary from secondary adrenal insufficiency.[1]
| Attribute |
Cosyntropin |
| Active ingredient |
Synthetic ACTH, amino acids 1-24 |
| Common product |
Cortrosyn |
| Typical dose |
0.25 mg |
| Route |
Intravenous or intramuscular |
| Primary use |
ACTH stimulation testing |
| Therapeutic category |
Diagnostic endocrine agent |
| Main customers |
Hospitals, endocrinology clinics, laboratories |
| Market type |
Mature, low-volume injectable |
| Substitution |
Limited for routine ACTH stimulation testing |
| Patent profile |
Legacy product with no meaningful remaining composition-of-matter protection |
Cosyntropin is not primarily a chronic-use drug. Demand is tied to the number of diagnostic evaluations, hospital protocols, endocrine referrals, and laboratory capacity.
How large is the cosyntropin market?
The global cosyntropin market is difficult to quantify because manufacturers and market-research providers do not consistently report product-level sales. Public company filings generally combine cosyntropin with other specialty pharmaceuticals or report it without a complete global market denominator.
The commercially relevant market is small relative to major endocrine therapies. Its value is supported by several factors:
- The product is an injectable diagnostic rather than a commodity oral medicine.
- Hospitals require reliable access when adrenal insufficiency is suspected.
- Clinical protocols often favor cosyntropin as the standard stimulation agent.
- The number of suppliers is limited compared with high-volume generic drugs.
- Shortages can increase purchasing urgency and transaction prices.
The market does not have the growth profile of GLP-1 medicines, oncology biologics, or specialty immunology products. Unit demand is relatively stable. Revenue growth, when it occurs, is more likely to come from price, channel mix, contract changes, and restored supply than from a large increase in patient volume.
What drives cosyntropin demand?
Demand is driven by:
- Evaluation of primary adrenal insufficiency, including Addison’s disease.
- Evaluation of secondary or tertiary adrenal insufficiency.
- Testing after chronic glucocorticoid exposure.
- Endocrine referrals and inpatient diagnostic workups.
- Hospital protocol adoption.
- Availability of cortisol assay services.
- Changes in awareness or diagnosis of adrenal disorders.
The drug’s use is diagnostic, so demand is less sensitive to prescription refills and adherence than chronic therapies. A hospital may purchase the product irregularly but still require inventory because the test is difficult to replace when an urgent diagnostic workup is underway.
Who manufactures cosyntropin?
Amphastar Pharmaceuticals is the most visible U.S. commercial supplier through Cortrosyn. The company has identified Cortrosyn as part of its specialty pharmaceutical portfolio and has discussed the product in public filings alongside other marketed products.[2]
The U.S. market has also experienced supply from generic or alternative suppliers at different times. Product availability has varied by presentation, manufacturer, wholesaler inventory, and regulatory status. A supplier’s approval does not guarantee continuous commercial distribution.
| Commercial factor |
Market effect |
| Amphastar’s Cortrosyn position |
Provides an established branded reference product |
| Generic entry |
Limits long-term pricing power |
| Few active suppliers |
Increases shortage and allocation risk |
| Hospital purchasing |
Makes contract access and wholesaler inventory important |
| Injectable manufacturing |
Creates sterility, fill-finish, and quality risks |
| Low unit volume |
Reduces the incentive for many manufacturers to enter |
| Diagnostic dependence |
Supports recurring baseline demand |
The commercial structure resembles other mature injectable markets in which the molecule is old but the manufacturing and distribution requirements remain demanding.
What is the financial trajectory for cosyntropin?
Cosyntropin has a stable but limited financial trajectory. It can generate attractive gross margins during periods of constrained supply, but it does not have the revenue scale or growth drivers associated with a high-volume primary-care product.
Amphastar does not provide a consistently separated, comprehensive cosyntropin income statement covering global sales, gross profit, operating expenses, and cash flow. Public disclosures therefore support a directional assessment rather than a complete standalone financial model.[2]
Base-case financial outlook
The base case is low-single-digit unit growth with revenue performance determined primarily by price and supply continuity. The product should remain commercially relevant because:
- The diagnostic use is established.
- Clinical alternatives are less convenient or less standardized.
- The product is difficult to replace during a hospital workup.
- Manufacturing competition remains narrower than for many oral generics.
The principal constraint is market size. Even a meaningful price increase produces a limited absolute contribution to a diversified pharmaceutical company.
Upside case
The strongest upside scenario is sustained supply disruption affecting competing products while the principal supplier maintains manufacturing continuity. That environment can produce:
- Higher average selling prices.
- Increased wholesaler orders.
- Lower discounting.
- Greater hospital inventory purchases.
- Temporary market-share gains.
The upside is usually episodic. It is not equivalent to durable volume expansion because diagnostic testing demand does not increase proportionately with product price.
Downside case
The downside scenario involves new generic supply, successful manufacturing remediation by competitors, or hospital purchasing pressure. Possible effects include:
- Lower net prices.
- Reduced market share for the branded product.
- More frequent formulary substitution.
- Higher chargebacks and rebates.
- Lower returns on a specialized injectable manufacturing line.
A further risk is that a hospital responds to supply disruption by using an alternative diagnostic strategy, such as an insulin tolerance test or other endocrine evaluation pathway, although these substitutes are not interchangeable in every patient.
How does cosyntropin compare with competing diagnostic options?
Cosyntropin remains the practical standard for many ACTH stimulation tests, but several alternatives exist.
| Diagnostic option |
Role |
Commercial implication |
| Cosyntropin stimulation test |
Common evaluation of adrenal reserve |
Supports recurring product demand |
| Insulin tolerance test |
Alternative assessment of hypothalamic-pituitary-adrenal function |
More complex and less convenient |
| Metyrapone testing |
Alternative assessment of the HPA axis |
Limited use and operational complexity |
| CRH stimulation testing |
Specialized pituitary or HPA-axis evaluation |
Narrower use |
| Endogenous ACTH and cortisol testing |
Supports diagnosis but does not replace stimulation in all cases |
Complementary demand |
Cosyntropin’s competitive strength is operational simplicity. It is familiar to endocrinologists, can be administered in hospital and outpatient settings, and integrates with established cortisol-testing workflows.
Its weakness is that the product remains dependent on a diagnostic procedure. It does not create recurring revenue from long-term treatment, and clinical use can vary with institutional protocols.
What patents protect cosyntropin?
Cosyntropin has no meaningful remaining patent barrier based on its age and long-standing clinical use. The active ingredient is a synthetic peptide fragment of ACTH that has been commercially available for decades. Any original composition, formulation, or product patents would have expired long ago.
The remaining competitive barriers are regulatory and operational rather than patent-based:
- FDA approval of the specific injectable product.
- Sterile manufacturing capability.
- Stability and container-closure requirements.
- Validated analytical testing.
- Reliable supply of peptide active ingredient.
- Hospital and wholesaler contracting.
- Manufacturing history and quality compliance.
Are there formulation patents for cosyntropin?
No commercially important, durable formulation patent estate is generally associated with standard cosyntropin injection products. A manufacturer may hold process know-how, manufacturing documentation, trade secrets, or product-specific regulatory data, but those protections do not create the same market exclusivity as an active patent.
The most relevant proprietary advantage is execution: maintaining a compliant sterile supply chain and avoiding product discontinuity.
Are there method-of-use patents for cosyntropin?
The core diagnostic use of cosyntropin is established and generic. No widely recognized active method-of-use patent is required to maintain the principal market. New diagnostic protocols could potentially generate patent claims, but such claims would need to survive validity, written-description, enablement, and obviousness scrutiny. They would not automatically protect the broader cosyntropin market.
When did cosyntropin lose exclusivity?
Cosyntropin lost meaningful innovator exclusivity decades ago. The current market is governed primarily by abbreviated new drug application competition, product-specific approvals, manufacturing capacity, and commercial distribution.
There is no modern small-molecule-style exclusivity window supporting premium pricing. Any present price premium reflects brand recognition, supply reliability, contracts, and shortage conditions rather than remaining regulatory exclusivity.
What is the FDA and Orange Book status of cosyntropin?
Cosyntropin products are FDA-regulated prescription injectables. Cortrosyn has an established FDA regulatory history and is listed in FDA product and labeling databases.[1,3]
The key regulatory points are:
- The product is an injectable diagnostic agent.
- The reference product has a long commercial history.
- Generic competition can proceed through abbreviated applications where the applicant satisfies FDA requirements.
- Product availability can differ from formal approval status.
- Orange Book listing status should be reviewed at the individual product and strength level.
The Orange Book does not create exclusivity for an old product merely because a branded product remains marketed. Patent listings, if any, must be evaluated product by product. Cosyntropin’s principal competitive issues are not expected to arise from Paragraph IV patent litigation.
Are there Paragraph IV challenges involving cosyntropin?
Cosyntropin does not present the type of active patent litigation profile associated with recently approved branded drugs. Because the principal composition and diagnostic use are long established, a Paragraph IV challenge would have limited strategic value unless directed at a specific, enforceable product or formulation patent.
The realistic generic-entry pathway is ordinary regulatory competition rather than a high-value patent dispute. Market entrants are more likely to compete on approval, supply reliability, pricing, and wholesaler access.
What litigation and settlement risks affect cosyntropin?
The principal legal risks are commercial and regulatory:
- Product liability involving diagnostic use or administration.
- Manufacturing or quality disputes.
- Distribution and supply-contract disputes.
- FDA enforcement related to sterile injectable production.
- False-claims or reimbursement issues involving diagnostic billing.
- Antitrust scrutiny if supply becomes highly concentrated.
A major patent settlement is not a central feature of the cosyntropin market. The absence of a large active patent estate reduces litigation barriers but also limits the ability of a supplier to defend premium pricing through intellectual-property rights.
What manufacturing and intellectual-property barriers exist?
Cosyntropin’s manufacturing barriers are moderate. The active ingredient is old, but the finished product requires controlled sterile production and validated quality systems.
Key manufacturing risks include:
- Sterility assurance.
- Peptide handling and characterization.
- Fill-finish capacity.
- Vial and stopper compatibility.
- Stability through shelf life.
- Batch release testing.
- Supplier qualification.
- Regulatory inspection outcomes.
These barriers can support temporary market concentration. They do not create permanent exclusivity. A new entrant with adequate capital, regulatory expertise, and sterile manufacturing access can compete without inventing a new molecule.
How exposed are pharmaceutical companies to cosyntropin revenue?
Cosyntropin is generally a small product relative to a diversified pharmaceutical company’s total revenue. Its strategic value can exceed its absolute revenue contribution when it is one of a limited number of specialty injectables with recurring hospital demand.
For Amphastar, Cortrosyn is relevant to the specialty-product portfolio, but corporate performance is more heavily influenced by larger products and development programs. Investors should assess:
- Product-level net sales where disclosed.
- Gross margin relative to other injectables.
- Inventory and back-order trends.
- Wholesaler concentration.
- Manufacturing capacity utilization.
- FDA inspection outcomes.
- Price changes after shortage resolution.
The product is more likely to affect portfolio mix and margin quality than to determine total-company growth.
What generic launch scenarios exist for cosyntropin?
Scenario 1: Stable multi-supplier market
Several suppliers maintain reliable inventory. Prices gradually decline, hospitals use formulary substitution, and Cortrosyn retains share through familiarity and supply performance.
Scenario 2: Shortage-led price expansion
One or more suppliers encounter manufacturing or distribution problems. The remaining supplier gains volume and pricing power. Revenue rises temporarily, but the benefit weakens once supply normalizes.
Scenario 3: Aggressive generic erosion
A new supplier secures approval and commercial distribution, offering lower prices to hospital systems and wholesalers. The branded product retains customers that value continuity but loses price-sensitive accounts.
Scenario 4: Persistent concentrated supply
Regulatory or manufacturing barriers prevent broad generic participation. Prices remain elevated, but the market remains volume constrained. Revenue is stable to modestly higher, with continuing shortage risk.
ASHP and FDA shortage records are important leading indicators because cosyntropin demand is relatively predictable while supply can change abruptly.[4,5]
What licensing deals affect cosyntropin?
No major recent licensing transaction is central to the commercial outlook. The market is primarily controlled through product ownership, acquisitions, distribution arrangements, and manufacturing agreements rather than innovation-driven licensing.
Historical rights transfers can matter where a company acquires an established product, its NDA, or commercial rights. The economic value of such a transaction depends on:
- Remaining commercial life.
- Manufacturing control.
- FDA regulatory ownership.
- Hospital contracts.
- Supply history.
- Product-specific liabilities.
Because the molecule is off-patent, licensing value is based on cash flow and distribution access rather than protected future innovation.
What is the geographic coverage of the cosyntropin market?
The United States is the most commercially visible market because Cortrosyn and other FDA-approved products have established hospital distribution. International markets vary in product naming, approval status, reimbursement, and availability.
Geographic expansion is constrained by:
- Country-specific marketing authorization.
- Peptide and injectable registration requirements.
- Local hospital procurement.
- Reimbursement rules.
- Import and serialization requirements.
- Regional sterile manufacturing capacity.
A company cannot assume that U.S. approval translates into broad international sales. The market is fragmented by national regulatory and purchasing systems.
Key Takeaways
- Cosyntropin is a mature diagnostic injectable used mainly for ACTH stimulation testing.
- Cortrosyn is the principal U.S. branded reference product associated with Amphastar.
- The market is small, stable, and operationally important to hospitals despite limited volume.
- Financial performance is driven by supply continuity, pricing, and hospital contracts rather than patent exclusivity.
- Original composition and diagnostic-use patent barriers have expired.
- Paragraph IV litigation and settlement activity are not central market drivers.
- Sterile manufacturing, quality compliance, and distribution access are the principal barriers to entry.
- Shortages can create temporary revenue and margin expansion.
- Generic entry would pressure pricing, but limited market size may restrict the number of durable suppliers.
- Cosyntropin is unlikely to materially drive diversified pharmaceutical-company revenue, though it can contribute attractive specialty-product margins.
FAQs
Is cosyntropin a high-growth pharmaceutical product?
No. Cosyntropin is a mature diagnostic product with relatively stable demand. Revenue growth is more likely to reflect pricing, supply shortages, and commercial mix than significant unit expansion.
Can generic manufacturers replace Cortrosyn?
Yes. Approved generic cosyntropin products can compete with Cortrosyn, subject to FDA approval and commercial availability. Hospital purchasing may favor the lowest-cost supplier, but reliability and shortage performance remain important.
Does cosyntropin have biosimilar risk?
No. Cosyntropin is a synthetic peptide drug, not a biologic requiring the FDA biosimilar pathway. Competition generally proceeds through conventional pharmaceutical approval pathways rather than biosimilar applications.
What is the main investment risk in cosyntropin?
The main risk is market compression after supply normalizes or new suppliers enter. A supplier benefiting from shortage pricing can experience revenue and margin declines when competitors restore inventory.
Could new diagnostic technologies reduce cosyntropin demand?
Yes, but a substantial decline would require broad adoption of alternative adrenal-function tests that are clinically accepted, reimbursed, and operationally easier than the ACTH stimulation test. Current demand is supported by established clinical practice and laboratory infrastructure.
References
-
U.S. Food and Drug Administration. (n.d.). Cortrosyn (cosyntropin) prescribing information. FDA Drugs@FDA.
-
Amphastar Pharmaceuticals, Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2023. U.S. Securities and Exchange Commission.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA, Center for Drug Evaluation and Research.
-
American Society of Health-System Pharmacists. (n.d.). Drug shortages: Cosyntropin injection. ASHP Drug Shortage Resource Center.
-
U.S. Food and Drug Administration. (n.d.). Drug shortages database. FDA Drug Shortages.
